{"id":35056,"date":"2024-02-05T13:33:18","date_gmt":"2024-02-05T08:03:18","guid":{"rendered":"https:\/\/prevalentindia.in\/index.php\/2024\/02\/05\/morepen-laboratories-limited-q3-fy24-ebitda-surges-by-151-per-cent-net-profit-records-a-remarkable-256-per-growth\/"},"modified":"2024-02-05T13:33:18","modified_gmt":"2024-02-05T08:03:18","slug":"morepen-laboratories-limited-q3-fy24-ebitda-surges-by-151-per-cent-net-profit-records-a-remarkable-256-per-growth","status":"publish","type":"post","link":"https:\/\/prevalentindia.in\/index.php\/2024\/02\/05\/morepen-laboratories-limited-q3-fy24-ebitda-surges-by-151-per-cent-net-profit-records-a-remarkable-256-per-growth\/","title":{"rendered":"Morepen Laboratories Limited\u2019 Q3 FY24 EBITDA Surges by 151 per cent, Net Profit Records a Remarkable 256 per Growth"},"content":{"rendered":"
\n

Mumbai (Maharashtra) [India], February 5<\/strong>: Morepen Laboratories Limited\u00a0(NSE:\u00a0MOREPENLAB, BSE: 500288),\u00a0is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.\u00a0The Company reported its unaudited Q3FY24 financial results.<\/p>\n

Key Financial Highlights (Consolidated):<\/p>\n

Consolidated Key Financial Highlights Q3 FY24:<\/p>\n

-Total Income of\u00a0\u20b9\u00a0448.62 Cr, YoY growth of 28%<\/p>\n

-EBITDA of\u00a0\u20b9\u00a054.64 Cr, YoY growth of 151%<\/p>\n

-EBITDA Margin of 12.18%, YoY growth of 596 Bps<\/p>\n

-Net Profit of\u00a0\u20b9\u00a031.99 Cr, YoY growth of 256%<\/p>\n

-NPM (%) of 7.13%, YoY growth of 456 Bps<\/p>\n

-EPS of\u00a0\u20b9\u00a00.63, YoY growth of 255.72%<\/p>\n

Consolidated Key Financial Highlights 9M FY24:<\/p>\n

-Total Income of\u00a0\u20b9\u00a01277.09 Cr, YoY growth of 21%<\/p>\n

-EBITDA of\u00a0\u20b9\u00a0119.97 Cr, YoY growth of 79%<\/p>\n

-EBITDA Margin of 9.39%, YoY growth of 306 Bps<\/p>\n

-Net Profit of\u00a0\u20b9\u00a067.88 Cr, YoY growth of 123%<\/p>\n

-NPM (%) of 5.32%, YoY growth of 244 Bps<\/p>\n

-EPS of\u00a0\u20b9\u00a01.33, YoY growth of 121.67%<\/p>\n

Q3 & 9M FY24 Performance Insights<\/p>\n

Segments Wise Performance<\/p>\n

\n\n\n\n\n\n\n\n
\u00a0Particulars (\u20b9\u00a0Cr)<\/td>\nQ3 FY24<\/td>\nQ3 FY23<\/td>\nRaised<\/td>\n<\/tr>\n
API<\/td>\n253.21<\/td>\n211.46<\/td>\n^20%<\/td>\n<\/tr>\n
Devices<\/td>\n106.11<\/td>\n85.57<\/td>\n^24%<\/td>\n<\/tr>\n
Formulation<\/td>\n65.15<\/td>\n46.41<\/td>\n^40%<\/td>\n<\/tr>\n
DR.MOREPEN -OTC<\/td>\n21.29<\/td>\n21.99<\/td>\n-3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Geographical Revenue Breakup<\/p>\n

\n\n\n\n\n\n
\u00a0Particulars (\u20b9\u00a0Cr)<\/td>\n\u00a0Q3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 FY24<\/td>\n9M FY24<\/td>\n<\/tr>\n
Domestic Revenue<\/td>\n\u00a0271<\/td>\n829<\/td>\n<\/tr>\n
International Revenue<\/td>\n\u00a0178<\/td>\n448<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Commenting on the performance,\u00a0Mr. Sushil Suri \u2013 Joint Managing Director\u00a0of\u00a0Morepen Laboratories Limited\u00a0said,\u201dIn the backdrop of a steadily growing pharmaceutical market, our products are experiencing robust demand. Through a dedicated focus on cost control measures, we have achieved an impressive 151% increase in EBITDA and a remarkable 256% rise in net profit. As we maintain a resilient presence both in the Indian and international markets, we are optimistic about future growth opportunities.<\/p>\n

Our success is rooted in continuous product development initiatives and a deliberate expansion strategy in international markets. Noteworthy accomplishments include advancements in intellectual property, the successful development of new APIs, and strategic capacity expansions. These initiatives reflect our unwavering commitment to innovation and growth, solidifying Morepen Laboratories as a key player in the dynamic pharmaceutical industry.\u201d<\/p>\n

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Mumbai (Maharashtra) [India], February 5: Morepen Laboratories Limited\u00a0(NSE:\u00a0MOREPENLAB, BSE: 500288),\u00a0is engaged in the business of manufacturing, producing, developing<\/p>\n","protected":false},"author":1,"featured_media":35057,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[575],"class_list":["post-35056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business"],"_links":{"self":[{"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/posts\/35056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/comments?post=35056"}],"version-history":[{"count":0,"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/posts\/35056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/media\/35057"}],"wp:attachment":[{"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/media?parent=35056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/categories?post=35056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prevalentindia.in\/index.php\/wp-json\/wp\/v2\/tags?post=35056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}